Loading...
•
Jun 30, 2020
Ecolab Q2 2020 Earnings Report
Ecolab's performance was significantly impacted by COVID-19, with strong growth in Healthcare and Life Sciences offset by declines in Institutional and Other segments. The separation of ChampionX business also affected the results.
Key Takeaways
Ecolab's second quarter results were impacted by COVID-19, with a 15% decrease in reported sales. Adjusted EPS from continuing operations was $0.65, a 49% decrease. The Healthcare and Life Sciences segment showed strong growth, while the Institutional segment was heavily impacted by COVID-19 shutdowns.
Reported sales from continuing operations decreased by 15%.
Reported diluted EPS from continuing operations decreased by 63% to $0.44.
Adjusted diluted EPS from continuing operations decreased by 49% to $0.65.
Free cash flow from continuing operations was $229 million.
Revenue by Segment
Forward Guidance
Due to the uncertain outlook regarding the full extent of COVID-19’s impact on the global economy and its longevity, Ecolab is not providing either quarterly or annual earnings forecasts.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...